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Abstract The hormone binding site of rat and human natriuretic 
peptide clearance receptor (NPR-C), a single transmembrane 
receptor, has been further refined by mutagenesis. In addition to 
residue 188 (rat Ala, human Ile), which completely inverts the 
pharmacology of the rat and human receptors [Engel et al. (1994) 
J. Biol. Chem. 269, 17005-17008], we report a second key residue 
at position 205 (rat Tyr, human Asn) which modulates affinity to 
a limited number of ligands. Orthologous mutation of both resi- 
dues results in tighter binding for human and weaker binding for 
rat NPR-C. The ligand binding fold of the receptor is formed by 
at least the first half of the extracelhilar domain containing two 
intramolecular disulfide loops, with the two affinity-modulating 
residues 188 and 205 in the second loop. 
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dues Cys 428 and Cys 431 (for the splice variant NPR-C6) are 
involved in NPR-C homodimer formation while the remaining 
four cysteine residues form two intramolecular loops (Cys 63- 
Cys 9~ and Cys168-Cys216). In a previous paper we reported the 
sequence analysis and functional expression of rat NPR-C, 
which shows a higher affinity to all natriuretic peptides com- 
pared to the human receptor [9]. Orthologous mutagenesis at
position 188 for rat and human NPR-C results in a complete 
reversal of the pharmacology of both receptors [9]. In this paper 
we report he detection of a second residue at position 205 with 
a more specific influence on binding to a certain number of 
naturally occurring and synthetic ligands. Double mutations as 
well as alanine mutations at positions 188 and 205 further 
delineate differences in hormone binding between rat and 
human NPR-C. 
2. Materials and methods 
1. Introduction 
The natriuretic peptides (NPs) are vasoactive hormones 
which play an important role in the regulation of body fluid, 
electrolyte balance and blood pressure. As antagonists o the 
renin-angiotensin ystem, vasopressin, and endothelin, their 
potential use as drugs for hypertension, acute renal failure and 
heart failure has been considered. The three members of the 
family, ANP and BNP which are produced primarily in the 
heart [1], and CNP which is expressed by endothelial cells [2], 
share as a common motif a 17-amino acid loop formed by a 
disulfide bond. Their action is transmitted by two classes of 
natriuretic peptide receptors (NPRs), the receptor guanylyl 
cyclases NPR-A and NPR-B [3], and the clearance receptor 
NPR-C which lacks both the kinase-like and the guanylyl 
cyclase domains of NPR-A and NPR-B [4]. The physiological 
role of NPR-C is to mediate the metabolic learance of the 
hormones, but it also plays a role in signal transduction by 
G-protein coupling to mediate phosphoinositide hydrolysis and 
inhibition of adenylyl cyclase [5,6], 
Recently, site-directed mutagenesis n combination with 
mass spectroscopy helped to elucidate the topology of the ex- 
tracellular domain of NPR-C [7,8]. The juxtamembrane resi- 
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Abbreviations: ANP, atrial natriuretic peptide; BNP, brain natriuretic 
peptide; CNP, C-type natriuretic peptide; rANE rat ANP (28 amino 
acids); hANE human ANP (28 amino acids); rBNP, rat BNP (32 amino 
acids); hBNP, human BNP (32 amino acids); cANF, des[Gln ~8, Ser jg, 
Gly 2°, Leu 2j, GIy22]ANF,23-NH2; NPR, natriuretic peptide receptor; 
IgG, Immunoglobulin G;C-IgG, NPR-C extracellular domain/IgG Fc 
fusion protein. 
2.1. Site-directed mutagenesis and expression ofIgG fusion proteins 
Site-directed mutagenesis was performed according to Kunkel et al. 
[10] using a Biorad mutagenesis k t and was verified by sequencing with 
Sequenase (US Biochemicals, Cleveland, OH). The extracellular do- 
main of rat and human NPR-C was expressed asIgG fusion proteins 
(C-IgG's) by Chinese hamster ovary cells in serum-free medium as 
previously described [9,11]. Conditioned media in appropriate dilutions 
was directly used for the solid phase binding assay. 
2.2. Solid phase binding assay 
This assay was essentially aspreviously described [9]. In brief, C-IgG 
was bound to 96-well plates via Fc7 fragment specific, F(ab~) fragment 
rabbit anti-human IgG (Jackson ImmunoResearch, West Grove, PA). 
The amount of immobilized C-IgG was the same in each binding exper- 
iment so that the total amount of specifically bound tracer was approx- 
imately 15% of the total activity. Competition binding was performed 
by adding 15 pM ~25I-labeled rANP as tracer and serial dilutions of the 
competing peptides in PBS, 0.5% BSA, 0.01% Tween-20, pH 7.4. 
Natriuretic peptide analogs were either purchased from Bachem (Tor- 
rance, CA) and Peninsula Laboratories (Belmont, CA), or synthesized 
by solid phase methods at Genentech. After aliquoting, the amount of 
peptide in each vial was confirmed by quantitative amino acid analysis. 
3. Results 
3.1. Identification of the binding-modulating residue 205 
Expression of the extracellular domains as IgG fusion pro- 
teins provided useful tools to study the pharmacology of rat 
and human NPR-C in solid phase binding assays using 
[~251]rANP as tracer. Comparison of the observed binding affin- 
ities with tissue membrane preparations showed that the IgG 
constructs as well as the binding assay was consistent with the 
pharmacology observed for the native full-length receptor [9]. 
By using rat/human chimeras, we were able to locate the resi- 
dues modulating the binding behavior in the middle region of 
the extracellular domain between positions 106 and 266, where 
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Fig. 1. Modulation of rat and human C-IgG pharmacology b positions 
188 and 205. Shown is a representative competition binding experiment 
in which rat and human C-IgG and a number of orthologous mutants 
were tested for binding to hANP(F8Y) and hANP(G10K,R1 IS). The 
affinity of rY205N and hN205Y is in between the high affinity state of 
rat C-IgG or hI188A and the low affinity state of human C-IgG and 
rA188I. 
rat and human NPR-C differ by 11 residues. Orthologous ite- 
directed mutagenesis of these residues resulted in the identifica- 
tion of residue 188, Ala in rat and Ile in human, which resulted 
in a reversal of the hormone binding properties of both recep- 
tors [9]. 
Naturally occurring natriuretic peptides were used to identify 
position 188 as mediating species specific differences. Testing 
of synthetic peptide analogs on position 188 mutant receptors 
confirmed the role of this site in determining the binding prop- 
erties of rat or human NPR-C. However, in testing synthetic 
peptides such as hANP(F8Y) [12], hANP(G10K,RI1S) [13], 
hANP(O-Met) [14] and cANF [15] on the full set of mutant 
receptors we have now identified a second mutant, rY205N, 
with an altered pharmacology which is in between the high 
affinity state of rat C-IgG and the lower affinity state of human 
C-IgG (Fig. 1). Again, rA188I exhibits the lower affinity bind- 
ing behavior of human C-IgG [9] which holds true for all natu- 
rally occurring as well as all truncated or modified versions of 
the natriuretic peptides tested (exemplified by hANP(F8Y) and 
hANP(G10K,R1 IS) in Fig. 1). In contrast, rY205N shows a 
4-5-fold loss of affinity towards synthetic peptides such as 
hANP(F8Y), hANP(G 10K,R 11 S) and hANP(O-Met) whereas 
all other rat receptor mutants conserve the binding behavior of 
wild type rat C- IgG (Fig. I). The orthologous mutation on the 
human receptor verifies this observation; while hI188A resem- 
bles the higher affinity state of the rat C-IgG, hN205Y binds 
these synthetic analogs tighter than wild type human C-IgG 
(Fig. 1). Therefore, both residues of the rat receptor, Ala '88 as 
well as Tyr 2°5 contribute to high affinity binding whereas Ile ~s8 
and Asn 2°5 are responsible for the lower affinity state of the 
human receptor. 
3.2. Double alanine and orthologous mutations 
To analyze the impact of both residues 188 and 205 in rat and 
human C-IgG in concert, we changed both positions to alanine 
or made the orthologous double mutations (Table 1). Replace- 
ment of the rat wild type Tyr z°5 either by Asn (rY205N) or Ala 
(rY205A) has the same effect upon binding: Both mutants bind 
rANP, hANP, hANP(5-27) and CNP tighter than the rat wild 
type, whereas the affinities for hANP(F8Y), hANP(O-Met) and 
cANF decrease towards the values measured for human C-IgG 
(Table 1). hANP(GI0K ,R l lS )  and hBNP are bound by 
rY205N and rY205A in an intermediate affinity state between 
the natural rat and human receptors. The simultaneous change 
of both positions 188 and 205 (rA 188I,Y205N) disrupts binding 
of all analogs to the rat receptor, resulting in lower affinity 
binding. 
The analogous substitutions performed on human C-IgG 
had a less diverse impact on the observed binding affinities 
(Table 1). As stated above, hN205Y binds all hANP analogs, 
with the exception of hANP(O-Met), tighter than the wild type 
receptor. A dramatic increase in affinity is achieved by substi- 
tuting residue 188 as well. The alanine double mutation 
(hl188A,N205A) resembles hI188A,N205Y in all cases (Table 
1). These double mutants bind all analogs, with the exception 
of hANP(O-Met) and cANF, even tighter than wild type rat 
receptor, suggesting that the ligand binding sites of the two 
receptors have additional differences. This is an interesting 
observation since the rat receptor binds all analogs with higher 
Table 1 
ICs0 values (pM) of natriuretic peptides on wild type and mutated C-IgG fusion proteins a 
Natriuretic rANP hANP hANP hANP hANP hANP cANF rBNP hBNP CNP 
peptides (5-27) (F8Y) (GIOK,R11S) (O-Met) 
ratC-IgG 6.0+1.0 6.6-+2.1 32.4+9.2 49.0-+16.1 37.3-+17.8 32.8+7.6 368-+118 32.7_+11.6 28.4_+12.8 16.4+3.6 
rA188I 9.1 + 3.8 12.1 -+ 5.4 53.8 -+ 17.1 324_+ 175 598_+ 173 501 _+ 98 1,247_+ 267 75.4_+ 9.5 283_+ 167 18.8 + 4.3 
rY205N 3.7_+0.9 3.2_+ 1.4 15.6+4.9 278+ 108 206_+47 501_+ 174 790_+263 36.7_+9.4 43.5_+20.0 11.4+ 1.1 
rY205A 3.3+ 1.1 3.7+ 1.1 22.6+4.9 370+ 139 168+57 857_+ 131 1,196_+717 35.6+ 14.5 55.9-+ 18.2 11.4-+ 1.0 
rA188I,Y205N 15.0 + 2.4 398 + 59 433 -+ 787 >5,000 >3,000 >10,000 not 367_+ 269 >6,000 42.8 _+ 13.4 
determined 
humanC-IgG 9.5+0.7 13.0+2.2 48.0+12.5 391+175 624+155 456_+72 761_+260 75.3_+21.7 328+118 25.5_+6.6 
hl188A 5.1 _+0.7 6.2+ 1.6 29.1 +3.1 47.7_+ 14.3 19.9_+6.5 54.9_+24.9 381_+ 108 25.4+3.7 18.1 +5.9 13.1+1.9 
hN205Y 7.5 + 2.5 10.7-+ 0.7 15.4-+ 2.8 279 + 81 197_+ 45 1,139-+ 35 753 _+ 157 73.9_+ 9.6 345_+ 36 21.9_+ 7.9 
hI188A,N205A 4.6 _+ 1.4 6.5 _+ 3.0 21.4 _+ 3.4 28.1 -+ 10.9 21.5 + 7.1 98.2 + 40.9 389 _+ 225 19.4 + 6.6 10.5 -+ 4.4 14.9 -+ 5.2 
hI188A,N205Y 4.5 + 3.1 4.2 + 0.6 23.9-+ 9.0 25.3 _+ 5.5 14.6 + 3.9 41.5_+ 9.5 not 21.5_+ 7.1 13.4 + 6,6 15.1 + 6.0 
determined 
alCs0 values, the doses required to inhibit 50% of []25I]rANP binding to the receptors, are depicted as mean + standard eviation from at least hree 
independent experiments and were determined by a 4 parameter equation, a + (d - a)/[l + exp(b(c - x))], using the KaleidaGraph program. 
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Fig. 2. Binding affinities of rat and human C-IgG mutants relative to 
rat WT. The binding behaviour of the natriuretic peptides are differ- 
ently affected by changes in position 205 of the receptor which is 
exemplified by hANP and hANP(F8Y). Data were taken from 
Table 1. 
affinity than the human receptor and suggests that further work 
with chimeric and mutant receptors have to be imployed to 
identify additional residues involved in modulating ligand bind- 
ing. 
4. Discussion 
In the present study we have refined the molecular basis of 
the different pharmacology ofrat and human NPR-C where the 
human receptor is more sensitive to changes in ligand structure 
than the rat receptor. While orthologous mutation at position 
188 is sufficient o switch the overall binding behavior of both 
receptors [9], residue 205, Tyr in rat and Asn in human NPR-C, 
has a more distinct influence on binding of only a few analogs 
and was only detected in competition binding assays using 
synthetic analogs such as hANP(F8Y), hANP(G10K,Rl lS) 
and hANP(O°Met). 
Based on the modulating effect of residue 205 the hormone 
analogs presented in Table 1 can be divided into two groups 
depending on whether their affinity is only slightly or dramati- 
cally influenced. The first group is exemplified by hANP in Fig. 
2a and comprises in addition rANE hANP(5-27) and CNE 
Even if the observed effects are only on the order of 2-3-fold 
the reproducibility of the effect suggests that it is significant. 
Replacement of rat Tyr 2°5 by Asn or Ala slightly increases the 
binding properties. Simultaneous replacement of Ala ~88 by Ile 
decreases the affinities for these ligands even beyond human 
wild type so that there is obviously no additivity of both muta- 
tional effects. Replacement of the human Asn 2°5 by Tyr and Ala 
has a similar minor positive ffect upon binding. More obvious 
effects at position 205 are observed in the second group com- 
prising the synthetic analogs and the BNPs (Fig. 2b). Binding 
of hANP(F8Y), hANP(G10K,Rl lS),  hANP(O-Met) and 
cANF is reduced in both rat mutants even to the level of the 
human receptor, resembling rA188I. On the human receptor, 
again, mutations at position 205 cause only smaller effects 
compared to those evoked by mutating position 188. 
Fig. 3 summarizes our current knowledge of the ligand bind- 
ing domain of NPR-C which is dictated by the two intramolecu- 
lar disulfide folds. Based on sequence comparison and muta- 
genesis, Iwashina et al. [16] identified residues His ~°4 and Trp ~°5, 
which are conserved in all three natriuretic peptide receptors, 
as essential for ligand binding. This data, together with our 
results, define only a small number of NPR-C residues that are 
involved in forming the ligand-receptor complex. The model 
presented in Fig. 3 does not assign specific contact sites for 
hormone binding due to the fact that markedly different pep- 
tide analogs lead to a similar effect on binding. Steric effects 
seem to play only a minor role since replacement of the rat 
(human) wild type Tyr 2°5 (Asn 2°5) either by Asn (Tyr) or Ala 
has a surprisingly similar effect given the difference in the side 
chain specific volume of these residues (Tyr: 193.6, Asn: 117.7, 
Ala: 88.6 A3). One explanation for our result may be a variable 
hormone/receptor interface if these side chains are in direct 
contact with the bound ligand. Alternatively, residues at 188 
NH 2 
S° $ 
63 
COOH 
Fig. 3. Structural model of the ligand binding site of NPR-C. Based on 
the folding pattern dictated by the intramolecular disulfide loops 
(Cys63-Cys 91 and Cysl6S-Cys 216) and four residues involved in hormone 
binding: His TM, Trp 1°5, Ala/Ile t88 and Tyr/Asn 2°5. 
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and 205 may not be in ligand contact and indirectly influence 
binding by changing side chain packing in the vicinity of the 
binding site. 
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